COSENTYX (secukinumab) - Ankylosing spondylitis

The Committee deems that the clinical benefit of COSENTYX (secukinumab) remains substantial in the MA indication.

Considering:

• demonstration of a superiority compared to placebo,
• the lack of evidence of a superiority compared to adalimumab,
• the absence of robust comparative data versus the other biological medicinal products available,

the Committee deems that COSENTYX (secukinumab) provides no clinical added value (CAV V) in the current care pathway, which includes the relevant comparators.